Canada - français - Health Canada

glaxosmithkline inc - mépolizumab - poudre pour solution - 100mg - mépolizumab 100mg - immunosuppressive agents

Canada - français - Health Canada

glaxosmithkline inc - mépolizumab - solution - 100mg - mépolizumab 100mg - immunosuppressive agents

Canada - français - Health Canada

glaxosmithkline inc - mépolizumab - solution - 100mg - mépolizumab 100mg - immunosuppressive agents

Canada - français - Health Canada

glaxosmithkline inc - mépolizumab - solution - 40mg - mépolizumab 40mg

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - mepolizumabum - solution injectable en stylo prérempli - mepolizumabum 100 mg, saccharum, dinatrii phosphas heptahydricus, acidum citricum monohydricum, polysorbatum 80 dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 1.0 ml. - eosinophiles asthma, egpa, crswnp, hes - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - mepolizumabum - solution injectable en seringue préremplie - mepolizumabum 100 mg, saccharum, dinatrii phosphas heptahydricus, acidum citricum monohydricum, polysorbatum 80 dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 1.0 ml. - eosinophiles asthma, egpa, crswnp, hes - biotechnologika

Union européenne - français - EMA (European Medicines Agency)

glaxosmithkline trading services - mepolizumab - asthme - les médicaments pour les maladies respiratoires obstructives, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - mepolizumabum - lyophilisat pour solution injectable - praeparatio cryodesiccata: mepolizumabum 100 mg, saccharum, dinatrii phosphas heptahydricus corresp. natrium 1.5-2 mg, polysorbatum 80, acidum hydrochloricum q.s. ad ph pro vitro. - zusatztherapie bei schwerem eosinophilem asthma, zusatztherapie bei erwachsenen mit egpa - biotechnologika